Inicio / Estudios Omega-3 / 2. Bibliograf�a en procesos inflamatorios
2. Bibliograf�a en procesos inflamatorios
Browning LM. n-3 Polyunsaturated fatty acids, inflammation and obesity-related disease. Proc Nutr Soc. 2003 May;62(2):447-53.
Calder PC. Dietary modification of inflammation with lipids. Proc Nutr Soc. 2002 Aug;61(3):345-58.
Calder PC. n-3 polyunsaturated fatty acids, inflammation, and inflammatory diseases. Am J Clin Nutr. 2006 Jun;83(6 Suppl):1505S-1519S.
Kew S, Mesa MD, Tricon S, Buckley R, Minihane AM, Yaqoob P. Effects of oils rich in eicosapentaenoic and docosahexaenoic acids on immune cell composition and function in healthy humans. Am J Clin Nutr. 2004 Apr;79(4):674-81.
Mesa Garc�a MD, Aguilera Garc�a CM, Gil Hern�ndez A. Importancia de los l�pidos en el tratamiento nutricional de las patolog�as de base inflamatoria. Nutr Hosp. 2006;21(Suppl.2):30-43.
Rupp H, Wagner D, Rupp T, Schulte LM, Maisch B. Risk stratification by the "EPA+DHA level" and the "EPA/AA ratio" focus on anti-inflammatory and antiarrhythmogenic effects of long-chain omega-3 fatty acids. Herz. 2004 Nov;29(7):673-85.
Sijben JW, Calder PC. Differential immunomodulation with long-chain n-3 PUFA in health and chronic disease. Proc Nutr Soc. 2007 May;66(2):237-59.
Thies F, Miles EA, Nebe-von-Caron G, Powell JR, Hurst TL, Newsholme EA, Calder PC. Influence of dietary supplementation with long-chain n-3 or n-6 polyunsaturated fatty acids on blood inflammatory cell populations and functions and on plasma soluble adhesion molecules in healthy adults. Lipids. 2001 Nov;36(11):1183-93.
2.1 EPA y DHA en procesos inflamatorios delimitados
EPA y DHA en artritis reumatoide
Ariza-Ariza R, Mestanza-Peralta M, Cardiel MH. Omega-3 fatty acids in rheumatoid arthritis: an overview. Semin Arthritis Rheum. 1998 Jun;27(6):366-70.
Astorga G, Cubillos A, Masson L, Silva JJ. Active rheumatoid arthritis: effect of dietary supplementation with omega-3 oils. A controlled double-blind trial. Rev Med Chil. 1991 Mar;119(3):267-72.
Bahadori B, Uitz E, Thonhofer R, Trummer M, Pestemer-Lach I, McCarty M, Krejs GJ. omega-3 Fatty acids infusions as adjuvant therapy in rheumatoid arthritis. JPEN J Parenter Enteral Nutr. 2010 Mar-Apr;34(2):151-5.
Calder PC. n-3 Polyunsaturated fatty acids, inflammation, and inflammatory diseases. Am J Clin Nutr. 2006;83(6):S1505-S1519.
Das Gupta AB, Hossain AK, Islam MH, Dey SR, Khan AL. Role of omega-3 fatty acid supplementation with indomethacin in suppression of disease activity in rheumatoid arthritis. Bangladesh Med Res Counc Bull. 2009 Aug;35(2):63-8.
Geusens P, Wouters C, Nijs J, Jiang Y, Dequeker J. Long-term effect of omega-3 fatty acid supplementation in active rheumatoid arthritis. A 12-month, double-blind, controlled study. Arthritis Rheum. 1994 Jun;37(6):824-9.
Kjeldsen-Kragh J, Lund JA, Riise T, Finnanger B, Haaland K, Finstad R, Mikkelsen K, F�rre O. Dietary omega-3 fatty acid supplementation and naproxen treatment in patients with rheumatoid arthritis. J Rheumatol. 1992 Oct;19(10):1531-6.
Kremer JM. Clinical studies of omega-3 fatty acid supplementation in patients who have rheumatoid arthritis. Rheum Dis Clin North Am. 1991 May;17(2):391-402.
Leeb BF, Sautner J, Andel I, Rintelen B. Intravenous application of omega-3 fatty acids in patients with active rheumatoid arthritis. The ORA-1 trial. An open pilot study. Lipids. 2006 Jan;41(1):29-34.
Llor X. Papel de los l�pidos de la dieta en los mecanismos de inflamaci�n, proliferaci�n, diferenciaci�n y muerte celular en el tracto intestinal. Gastroenterol Hepatol. 2003;26:507-13.
Ruggiero C, Lattanzio F, Lauretani F, Gasperini B, Andres-Lacueva C, Cherubini A. Omega-3 polyunsaturated fatty acids and immune-mediated diseases: inflammatory bowel disease and rheumatoid arthritis. Curr Pharm Des. 2009;15(36):4135-48.
Sperling RI. Dietary omega-3 fatty acids: effects on lipid mediators of inflammation and rheumatoid arthritis. Rheum Dis Clin North Am. 1991 May;17(2):373-89.
Venkatraman JT, Chu WC. Effects of dietary omega-3 and omega-6 lipids and vitamin E on serum cytokines, lipid mediators and anti-DNA antibodies in a mouse model for rheumatoid arthritis. J Am Coll Nutr. 1999 Dec;18(6):602-13.
EPA y DHA en enfermedad inflamatoria intestinal
Almallah YZ, El-Tahir A, Heys SD, Richardson S, Eremin O. Distal procto-colitis and n-3 polyunsaturated fatty acids: The mechanism(s) of natural cytotoxicity inhibition. Eur J Clin Invest. 2000;30:58-65.
Almallah YZ, Ewen SW, El-Tahir A, Mowat NA, Brunt PW, Sinclair TS, Heys SD, Eremin O. Distal proctocolitis and n-3 polyunsaturated fatty acids (n-3 PUFAs): the mucosal effect in situ. J Clin Immunol. 2000 Jan;20(1):68-76.
Almallah YZ, Richardson S, O'Hanrahan T, Mowat NA, Brunt PW, Sinclair TS, Ewen S, Heys SD, Eremin O. Distal procto-colitis, natural cytotoxicity, and essential fatty acids. Am J Gastroenterol. 1998;93:804-9.
Arrizabalga JJ. Manejo nutricional de la enfermedad inflamatoria intestinal. Endocrinol Nutr. 2007;54:151-68.
Ruggiero C, Lattanzio F, Lauretani F, Gasperini B, Andres-Lacueva C, Cherubini A. Omega-3 polyunsaturated fatty acids and immune-mediated diseases: inflammatory bowel disease and rheumatoid arthritis. Curr Pharm Des. 2009;15(36):4135-48.
Sharon P, Stenson WF. Enhanced synthesis of leukotriene B4 by colonic mucosa in inflammatory bowel disease. Gastroenterology. 1984;86:453-60.
Trebble TM, Arden NK, Wootton SA, Calder PC, Mullee MA, Fine DR, Stroud MA. Fish oil and antioxidants alter the composition and function of circulating mononuclear cells in Crohn disease. Am J Clin Nutr. 2004;80:1137-44.
Turner D, Shah PS, Steinhart AH, Zlotkin S, Griffiths AM. Maintenance of remission in inflammatory bowel disease using omega-3 fatty acids (fish oil): A systematic review and meta-analyses. Inflamm Bowel Dis. 2010 Jun 17.
2.2. EPA Y DHA en procesos inflamatorios sist�micos
Bannenberg G, Serhan CN. Specialized pro-resolving lipid mediators in the inflammatory response: An update. Biochim Biophys Acta. 2010 Dec;1801(12):1260-73.
The formation of endogenous autacoids derived from ω-3 PUFA may explain in part the well-known, essential roles of the ω-3 PUFA in human health and disease. More importantly the contribution of novel SPM to the benefits derived from dietary ω-3 FA are beginning to be appreciated with the identification of resolvins as potent autacoids that regulate the resolution phase of the acute inflammatory response [148]. The resolution phase of inflammation has its own regulation involving specific changes in cellular activity, and employment of specific lipid mediators and proteins. The novel endogenous structures of the resolvins, protectins and maresins as a genus function in this milieu, regulating both early (neutrophil traffic) and late responses (macrophage uptake and clearance of apoptotic granulocytes). Resolution is activated and accelerated by SPM, and both experimental animal systems and unbiased resolution indices are now in place to test the activity of pharmacological resolution directed interventions and their impact in active resolution. Further studies which aim to understand lipid mediator biosynthesis, tissue and stimulus-specific molecular signatures of resolution are likely to provide us with new ways to control inflammation and its unwanted side effect namely tissue damage and injury.
Bannenberg GL. Resolvins: Current understanding and future potential in the
control of inflammation. Curr Opin Drug Discov Devel. 2009 Sep;12(5):644-58.
An increasing number of studies that address the potent regulatory actions of endogenous ω-3 FA-derived anti-inflammatory mediators may be expected in the near future. The development of stable resolvin, protectin and maresin analogs, which harness the inherent structural features that determine susceptibility to degradation, will unlock the full therapeutic potential of these compounds to activate counter-regulatory and pro-resolving circuits. The development of remedies for inflammatory disease is no longer limited to merely inhibiting inflammation, but can now be rationally addressed through the specific activation of resolution, concurrent dampening of proinflammatory circuits and activation of tissue protection. These novel therapeutic approaches will become increasingly attractive as long as human dietary FA consumption remains essentially out of balance.
Browning LM, Krebs JD, Moore CS, Mishra GD, O'Connell MA, Jebb SA. The impact of long chain n-3 polyunsaturated fatty acid supplementation on inflammation, insulin sensitivity and CVD risk in a group of overweight women with an inflammatory phenotype. Diabetes Obes Metab. 2007 Jan;9(1):70-80.
de Roos B, Mavrommatis Y, Brouwer IA. Long-chain n-3 polyunsaturated fatty acids: new insights into mechanisms relating to inflammation and coronary heart disease. Br J Pharmacol. 2009 Sep;158(2):413-28. Epub 2009 May 5.
Hermsdorff H, Zulet MA, Bressan J, Mart�nez JA. Efecto de la dieta en la inflamaci�n cr�nica y de bajo grado relacionada con la obesidad y el s�ndrome metab�lico. Endocrin Nutr. 2008;55:409-19.
Itoh M, Suganami T, Satoh N, Tanimoto-Koyama K, Yuan X, Tanaka M, Kawano H, Yano T, Aoe S, Takeya M, Shimatsu A, Kuzuya H, Kamei Y, Ogawa Y. Increased adiponectin secretion by highly purified eicosapentaenoic acid in rodent models of obesity and human obese subjects. Arterioscler Thromb Vasc Biol. 2007;27;1918-25.
Micallef MA, Garg ML. Anti-inflammatory and cardioprotective effects of n-3 polyunsaturated fatty acids and plant sterols in hyperlipidemic individuals. Atherosclerosis. 2009 Jun;204(2):476-82.
Oz HS, Chen TS, Neuman M. Nutrition intervention: a strategy against systemic inflammatory syndrome. JPEN J Parenter Enteral Nutr. 2009 Jul-Aug;33(4):380-9. Epub 2009 Apr 14.
Recasens M, Ricart W, Fern�ndez-Real JM. Obesidad e inflamaci�n. Rev Med Univ Navarra. 2004;48(2):49-54.
Undurti N Das. Can essential fatty acids reduce the burden of disease(s)? Lipids Health Dis. 2008;7:9.